Catalog No.
KDE40105
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative competitive enzyme immunoassay technique. An antibody specific for Retatrutide has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled Retatrutide and then pipetted into the wells. Retatrutide in the sample competitively binds to the pre-coated antibody with biotin-labeled Retatrutide. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Retatrutide bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Retatrutide concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
125 - 8,000 ng/mL
Sensitivity
48.25 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
4141.5
|
876.8
|
162.7
|
4059.7
|
822.2
|
237.2
|
|
Standard deviation
|
582.7
|
157.1
|
29.0
|
505.4
|
144.0
|
45.7
|
|
CV (%)
|
14.1
|
17.9
|
17.8
|
12.4
|
17.5
|
19.3
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
LY3437943
Note
For Research Use Only.
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity., PMID:38367045
The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases., PMID:38471571
An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update., PMID:38471973
Gut hormones and appetite regulation., PMID:38511400
Top studies of 2023 relevant to primary care: From the PEER team., PMID:38626998
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions., PMID:38681750
Advancements in the management of obesity: a review of current evidence and emerging therapies., PMID:38685693
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?, PMID:38687506
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review., PMID:38723646
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?, PMID:38753454
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity., PMID:38843460
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial., PMID:38858523
Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials., PMID:38976545
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity., PMID:38984950
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide., PMID:39019866
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases., PMID:39096466
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy., PMID:39125772
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice., PMID:39212900
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology., PMID:39259982
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials., PMID:39305981
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials., PMID:39318607
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care., PMID:39335551
Retatrutide., PMID:39429457
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review., PMID:39458963
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation., PMID:39481534
The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity., PMID:39507873
The power of three: Retatrutide's role in modern obesity and diabetes therapy., PMID:39515565
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article., PMID:39676791
The First Triple Agonist for Antiobesity: Retatrutide., PMID:39724554
Why are we still in need for novel anti-obesity medications?, PMID:39726721
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials., PMID:39761578
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado., PMID:39776466
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis., PMID:39817343
Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP., PMID:39868848
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis., PMID:39911047
Emerging pharmacotherapies for obesity: A systematic review., PMID:39952695
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis., PMID:39968298
Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials., PMID:39980735
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines., PMID:40022548
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis., PMID:40040445
[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]., PMID:40042613
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities., PMID:40081498
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression., PMID:40094000
Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment., PMID:40126003
Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review., PMID:40206909
Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials., PMID:40207414
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials., PMID:40291085
Contractile effects of retatrutide in isolated mouse atrial preparations., PMID:40464942
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis., PMID:40471293
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis., PMID:40489581
For research use only. Not for human or drug use.
